浙江东方基因生物制品股份有限公司 关于选举独立董事 并调整专门委员会及委员的公告

Group 1 - The company announced the election of a new independent director, Chen Junze, following the resignation of the previous independent director, Li Bo, due to personal work reasons [1][2][3] - Chen Junze has extensive experience in the financial sector, having held various positions including Vice President at Zhejiang Equity Service Group and Chairman at Shanghai Yitong Investment Technology Co., Ltd. [3][4] - The board of directors approved the proposal to elect Chen Junze as an independent director and to adjust the membership of the specialized committees, which will take effect upon approval at the shareholders' meeting [1][2][3] Group 2 - The company’s subsidiary, Shanghai Wanzijian Biotechnology Co., Ltd., along with Healgen Scientific LLC, has recently obtained medical device registration certificates in China, Australia, and Singapore [5] - The newly registered products enhance the company's flow cytometry technology platform and expand the market for respiratory triple detection products internationally [5] - The company plans to hold its second extraordinary shareholders' meeting on November 20, 2025, to discuss the election of the new independent director and other matters [8][9][10]